Cellectis S.A. (0WA2.L)
- Previous Close
2.7180 - Open
2.6542 - Bid --
- Ask --
- Day's Range
2.3514 - 2.4300 - 52 Week Range
1.4840 - 3.6544 - Volume
3,740 - Avg. Volume
2,215 - Market Cap (intraday)
-- - Beta (5Y Monthly) 3.13
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.com231
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0WA2.L
Performance Overview: 0WA2.L
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0WA2.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0WA2.L
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-18.78%
Return on Equity (ttm)
-71.28%
Revenue (ttm)
24.52M
Net Income Avi to Common (ttm)
-71.89M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
67.36M
Total Debt/Equity (mrq)
109.72%
Levered Free Cash Flow (ttm)
-48.23M
Company Insights: 0WA2.L
0WA2.L does not have Company Insights